NCT02371668View on ClinicalTrials.gov

Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

February 25, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
H1N1 Influenza Healthy Volunteers
Interventions
BIOLOGICAL

CR6261

50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).

BIOLOGICAL

Placebo

Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02371668 - Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model | Biotech Hunter | Biotech Hunter